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The aim of the present study was to modify and validate a high-
performance liquid chromatographic (HPLC) method for
determining 2,3 and 2,5 dihydroxybenzoic acid (2,3-DHBA and
2,5-DHBA) from salicylic acid in human plasma. The mobile phase
was a mixture of sodium acetate/citrate (pH 2.5) 30 mM–methanol
(93:7, v/v). The injection volume was 10 µL. Retention time for 2,5-
DHBA, and 2,3-DHBA was 4.5 ± 0.10 and 5.8 ± 0.15 min,
respectively. The detection and quantification limits were 10 and 40
nM for 2,3-DHBA and 8 and 20 nM for 2,5-DHBA. Linearity was
evaluated in the range of 40–1600 nM for both metabolites. Inter-
and intra-analysis variation coefficient was below 10%. Good
recoveries of more than 99% were obtained for both metabolites
using this method.
Introduction
Oxidative stress (OS) results from an imbalance in the prooxi-
dant-antioxidant equilibrium favoring prooxidants, which can be
due to an excess of prooxidant substances, an antioxidant defi-
ciency, or by both factors simultaneously (1). The main oxidative
substances in biological systems are free radicals (FR). The
majority of the cell components are susceptible to FR, but
nucleic acids, lipids, proteins, and carbohydrates are their main
targets (2). Several diseases have been associated with OS, such
as inflammatory atherosclerosis, diabetes, Alzheimer’s diseases,
various types of cancer, and cardiovascular disorders (3,4).
A variety of biological markers have been developed for evalu-
ating OS, which specifically target the damage caused by FR or
the generation of FR in vivo, including lipids, proteins, and oxi-
dized DNA (5). Nevertheless, few methods directly determine
reactive oxygen species, especially the hydroxyl radical (OH•),
due to their short average lifespan. Furthermore, although the
antioxidant defense system can be increased or decreased in the
presence of OS, the determination of FR in fact indicates the
oxidative level present in the organism. Determination of OH• is
carried out by evaluating the generation of stable derivatives
such as salicylic acid (SAL), 2,3-dihydroxybenzoic acid (2,3-
DHBA) and comparing with CYP450 oxidation route, 2,5-dihy-
droxybenzoic acid (2,5-DHBA) using high-performance liquid
chromatography (HPLC) techniques (6–9). Because these
metabolites are stable and freely circulate in the bloodstream,
they can easily be detected and quantified in plasma (10,11).
Experimental
Reagents and chemicals
Analytical-grade 2,3-DHBA, 2,5-DHBA, and 3,4-dihydroxyben-
zoic acid (3,4-DHBA) from Sigma Aldrich (St. Louis, MO) were
used together with analytical-grade granular anhydrous sodium
acetate and sodium citrate dihydrated from J.T. Baker
(Phillipsburg, NJ). Methanol and ethyl acetate were HPLC grade
from J.T. Baker.
Chromatography
Samples were analyzed using an HP Agilent series 1100 chro-
matographic system consisting of a solvent delivery pump Model
G131A (Palo Alto, CA), an electrochemical detector Model 1049A,
a Waters Spherisorb 5-µm ODS2 reversed-phase column (25 ×
0.46-cm i.d.) (Milford, MA), and a ChemStation for LC3D soft-
ware, version A.08.03 (847) (Agilent).
Plasma samples preparation
The proposed method is based on the method by Coudray et al.
(7). One-hundred microliters of 3,4-DHBA (1000 nM) was added
to 400 µL plasma as an internal standard. A total of 100 µL mix-
ture containing 2,3-DHBA and 2,5-DHBA at known concentra-
tions (between 40 and 1600 nM) were added to 100 µL 1 M HCl.
The mix was vortexed for 30 s, and 3 mL of ethyl acetate was
added and then vortexed for another 1 min. Finally the tubes
were centrifuged at 2000 × g for 10 min. The resulting organic
layer was separated and evaporated by aeration. The sample was
reconstituted in 400 µL of mobile phase, and the injection
volume was of 10 µL.
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The HPLC system was equilibrated with the mobile phase con-
sisting of 30 mM acetate/sodium citrate (93:7, v/v) (pH
2.5)–methanol, varying the proportion of both solvents to find
the optimum, at a flow rate of 1.0 mL/min. The electrochemical
detection was optimized in order to found the adequate oxidation
potential that detected the signal of the analyzed metabolites.
The column was maintained at ambient temperature.
Validation procedure
The analytical method was validated in adherence to the FDA
Guidance for Industry: Bioanalytical Methods Validation and the
Official Mexican Norm NOM-177-SSA1-1998 in the following
parameters.
Linearity
Linearity was assessed within the range of 40–1600 nM for
solution and plasma, which covered the clinically expected
trough plasma levels.
Precision and accuracy
Intra-day validation was carried out using the runs of one day
(n = 5), while inter-day validation was assessed using data col-
lected in three days (n = 2). Three different concentrations were
analyzed within the linearity interval for 2,3-DHBA and 2,5-
DHBA in plasma. These concentrations were different from
those present in the calibration chart, although they were repre-
sentative of the linearity interval. Precision was characterized by
the coefficients of variation (CV%), whereas accuracy was
expressed as a percentage error (PE%) of nominal versus mea-
sured concentration.
Recovery
Recovery was assessed by determining three concentration
levels in plasma and solution (700, 1400, and 2000 nM). The
response of plasma samples, to which 2,3-DHBA and 2,5-DHBA
had been added at the aforementioned concentrations, were
compared to the response of the standard 2,3-DHBA and 2,5-
DHBA solutions at the same concentrations.
Quantification limit
The lowest working concentration level was determined in
quintuplicate, and it was determined to be valid if the values
obtained were within 20% and if the CV% was no greater than
20%.The limit of quantification of 2,5-DHBA was 20 nM with a
CV% of 5.57% and for 2.3-DHBA was 49 nM with a CV% of 0.3%.
Detection limits
The concentration at which the 2,3-DHB and 2,5-DHB signal
could be discerned from background noise in samples without
these compounds added was determined. The detection limits
were 10 nM for 2,3-DHBA and 8 nM for 2,5-DHBA.
Specificity
The specificity of the method was established by analyzing
samples from six random human volunteers that had no addi-
tives in them.
The stability in time of 2,3-DHBA, 2,5-DHBA, and 3,4-DHBA
in mobile phase was tested at different storage temperatures
(refrigeration and frozen).
Moreover, the HPLC method was preliminarily applied to
determine 2,3-DHBA and 2,5-DHBA concentrations from
healthy subjects treated with therapeutic single dose of aspirin
(500 mg).
When the aim of the study and the possible side effects of drug
administration had been explained to the subjects, a written
informed consent was requested and received. The
present work was approved by the Ethics and
Research Committee of the Durango General
Hospital of the Mexican Health Ministry.
Results and Discussion
We developed and validated a quick and sensitive
method for determining 2,3-DHBA, 2,5-DHBA, and
3,4-DHBA as an internal standard in human plasma
samples. Chromatographic conditions were investi-
gated, and the maximum resolution and sensitivity
of the method were obtained at 0.55 V oxidation
potential, 1.0 mL/min flow rate, and retention
times of 2,5-DHBA, 3,4-DHBA, and 2,3-DHBA were
4.5 ± 0.10, 5.2 ± 0.09, and 5.8 ± 0.15 min, respec-
tively (Table I). The injection volume was 10 µL.
The total run time of the method was 10 min, and
Table I. Retention Times of the Acid 2,5-DHBA, 3,4-DHBA, and
2,3-DHBA*
Metabolite Retention time (min)
2,5-DHBA 4.5 ± 0.10
3,4-DHBA 5.2 ± 0.09
2,3-DHBA 5.8 ± 0.15
* The retention time is expressed as mean ± standard deviation; n = 10. Room
temperature of 20 ± 3°C.
Figure 1. Standard chromatogram of plasmawith 1000 nM: (A) 2,5-DHBA acid, (B) 3,4-DHBA, and
(C) 2,3-DHBA and their corresponding retention times.
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standard chromatograms were obtained after injecting plasma
samples with 2,3-DHBA, 2,5-DHBA, and 3,4-DHBA added at a
1000 nM concentration (Figure 1).
The resolution was obtained using a Waters reversed-phase
column Spherisorb Phenyl (4.6 × 250 mm, 5 µm). We found the
optimum chromatographic conditions for its detection and
obtained higher sensitivity and resolution to an oxidation poten-
tial of 0.55 V, a mobile phase flow rate of 1 mL/min. The mobile
phase consisted of a mixture of acetate/30 mM sodium cit-
rate–methanol (93:7, v/v) at pH 2.5 plus metabolites in the dis-
solved phase with a running time of 15 min. The chromatogram
shows the retention times of the metabolites as shown in
Figure 1.
Linearity
Linearity of the method was established at the 40–1600 nM
range (Figure 2), with the following linear regressions: for 2,5-
DHBA acid: y = 1.9411 + 0.1032x, r = 0.9985 (p = 0.001) and for
2,3-DHBA acid: y = 8.4641 + 0.0916x; r = 0.9925 (p = 0.001).
Precision and accuracy
Inter- and intra-assay precision was determined by analyzing
three known concentrations (80, 200, and 1000 nM). Inter- and
intra-analysis CV% for 2,3-DHBA and 2,5-DHBA analytes were
less than 10% (Table II), which is below the acceptable 15% level
(12). The relative error did not exceed the ± 15% acceptance
limit in the three different concentrations levels that were tested
(Table II).
Recovery
The recovery of each metabolite was analyzed in quadruplicate
at the three concentration levels (80, 200, and 800 nM). Table III
shows that analyte recoveries were close to 100%, and the extrac-
tion efficiency ranged between 99.27–101.68% for 2,5-DHBA and
99.62–104.67% for 2,3-DHBA (CV% < 6%).
Sensitivity
The sensitivity was determined by evaluating the change in
response per unit concentration, whereas sensitivity is the slope
of the concentration-response curve, or change in response per
unit concentration.
The quantification limit for 2,5-DHBA acid was 20 nM with a
CV% of 5.57%, whereas for 2,3-DHBA it was 40 nM with a CV%
of 0.30%. The detection limits were 10 nM and 8 nM for 2,3-
DHBA and 2,5-DHBA, respectively.
Specificity
No endogenous interference was observed in the retention
times for the analytes, as noted in six chromatograms obtained
from the samples of healthy individuals without any added sub-
stances (not shown).
Stability
The stability of 2,3-DHBA, 2,5-DHBA, and 3,4-DHBA was
assessed in mobile phase. Results indicated the three analytes
were stable at 4 ± 2°C for at least 24 h and at –24 ± 1°C for a
month. After three months, the three analytes degraded in
plasma, in contrast the compounds in the solution, were stable
for six months at –24 ± 1°C.
In addition, in vivo detection of 2,3-DHBA produced was
tested. Typical chromatograms found from plasma blank, and
plasma added with metabolites and patient’s plasma samples are
presented in Figure 3.
The purpose of this work was to develop a quick and sensitive
chromatographic method for determining 2,3-DHBA, 2,5-
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Table II. Inter-Assay and Intra-Assay Precision and Accuracy of
Plasma Samples for Validation of the Method
2,5-DHBA 2,3-DHBA
Conc. Conc. PE CV Conc. PE CV
added (nM) found (nM) (%)* (%)* found (nM) (%) (%)
Inter-day (n = 5)
80 81.18 1.47 3.67 78.20 –2.25 1.19
200 201.89 0.94 4.82 208.21 4.10 5.64
800 786.89 –1.63 5.70 797.92 –0.26 3.39
Intra-day (n = 6)
80 81.43 1.79 3.86 79.55 –0.56 9.80
200 191.30 –4.35 5.93 201.89 0.94 7.33
800 776.52 –2.93 3.73 773.14 –3.35 2.31
* CV = coefficient of variation, calculated as (standard deviation/mean
concentration) × 100; PE = percentage error, calculated as
[(mean concentration – nominal concentration)/nominal concentration] × 100.
Figure 2. Linearity of the analytical method in plasma assessed by a calibration
curve of the acid 2,5-DHBA and 2,3-DHBA. Each point represents the average of
five measurements per concentration.
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DHBA, and 3,4-DHBA analytes. Reliability of the method was
determined by validating the method taking into account pre-
vious reports (6,7,10,13). The oxidation potential signal detected
from the metabolites that were analyzed (0.55 V) was lower than
that of Coudray et al., (7), which was 0.7 V, and others (6,10,13),
which ranged from 0.60 to 0.96 V (Table IV). The mobile phase
was similar to that used by Coudray et al. (7), varying only in the
amount of each compound used. Whereas Coudray et al. used
85:15 (v/v) 30 mM sodium acetate/citrate–methanol in their
method, the present work used a 93:7 (v/v) amount. The advan-
tages offered by this method is that the mobile phase flow rate
was higher than that used by these authors (1 mL/min versus 0.2
mL/min), which made the retention and run times shorter than
those of Coudray et al. (7) and others authors (6,10,13) (Table
IV). This in turn helped us to obtain better peak resolution.
Correlation of both metabolites indicates that more than 99%
of the peak area is explained by analyte concentration (12). Inter-
assay and intra-assay CV% for 2,3-DHBA and 2,5-DHBA were
below the 15% acceptance level established for this type of method
(Official Mexican Norm, 1998; Guidance for industry, 2001), indi-
cating that the method is highly precise. Furthermore, this
method is accurate because the percentage error was below 4.3%
and did not exceed ± 15% acceptance levels.
Analyte recoveries were close to 100% with ranges of
97.27–103.68% for 2,5-DHBA and 101.83–105.41% for 2,3-
DHBA. The quantification limit for 2,5-DHBA was 20 nM and 40
nM for 2,3-DHBA with a CV% ≤ 5.57%, which is well below the
acceptance limit of 20% (Official Mexican
Norm, 1998). No endogenous interference was
seen when analyzing six randomly selected
samples from healthy individuals, which pro-
vides evidence that this method is highly spe-
cific (Official Mexican Norm, 1998).
When healthy individuals were tested for pro-
duction of 2,3-DHBA, the metabolite produced
by an oxidation route by scavenging the OH•
free radical, our preliminary results showed a
small amount of it (6.0 ± 2.8 nM). Besides, in a
few monitored patients with controlled type 2
diabetes, the production of 2,3-DHBA reached
in plasma 7.6 ± 1.32 nM. Our results suggest OS
presence because of the increased 2,3-DHBA
production. Further investigations are needed
to assess the diagnostic value of quantifying this
metabolite as a marker in several diseases with
the presence of OS.
Future application
The method has been optimized successfully
to be implemented as a diagnosis test to eval-
uate oxidative stress in patients by increasing
production of the hydroxylated metabolite of
salicilates 2,3-DHBA in vivo. This was studied
because there are an increasing number of dis-
eases that are associated with OS, such as dia-
betes, atherosclerosis, cancer, inflammatory
process, Alzheimer’s, and cardiovascular dis-
eases (3,4).
The results of studies by Ghiselli et al. (14)
and Coudray and Favier (15) suggest that the
method of salicylate hydroxylation is useful to
reveal in vivo OS independently from the perox-
idation of lipids, and they support the hypoth-
esis that oxygen radicals are involved in
the pathogenesis of chronic complications of
diabetes.
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Table III. Recovery and Coefficient of Variation for 2,3-DHBA
and 2,5-DHBA Metabolites
Recovery (n = 3)
2,5-DHBA 2,3-DHBA
Conc. (nM) Mean (%) CV (%) Mean (%) CV (%)
80 101.68 5.79 101.83 4.12
200 99.27 4.50 104.67 5.69
800 101.10 3.90 99.62 1.84
Table IV. Comparison of Analytical Methods for Quantifying Metabolites 2,3 and 2,5-DHBA
Oxidation Flow Mobile Retention
potential rate phase time References
0.70 V 0.2 mL/min 30 mM acetate/sodium 2,3-DHBA = 22 min 7
citrate–methanol 2,5-DHBA = 19.6 min
(85:15, v/v) pH 3.9 3,4-DHBA = 27 min
0.77 V 0.5 mL/min 50 mM acetate/sodium citrate– 13
methanol–2-propanol (90:8:2, v/v) pH 2.5
0.60 V 1.0 mL/min 30 mM sodium citrate/27.7 2,3-DHBA = 10 6
mM acetate pH 4.75 2,5-DHBA = 12
0.96 V 0.9 mL/min 30 mM sodium citrate/27.7mM 2,3-DHBA = 7 10
acetate pH 4.75–methanol 2,5-DHBA = 8
(92.2:12.8, v/v) pH 2.5
0.55 V 1.0 mL/min 30 mM acetate/ sodium 2,3-DHBA = 5.8 min This study
citrate–methanol (93:7, v/v) pH 2.5 2,5-DHBA = 4.5 min
3,4-DHBA = 5.2 min
Figure 3. Characteristic chromatograms: (A) blank human plasma, (B) blank plasma spiked with 1000
nM of 2,5-DHBA, 1; the internal standard 3,4-DHBA, 2; and 2,3-DHBA, 3; and (C) plasma sample from
a healthy subject administered with a single dose of aspirin (500 mg, oral route) and monitored for the
detection of the three metabolites.
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To the authors’ knowledge, the study of Strolin-Benedetti et al.
(16) showed for the first time that induction of some but not all
P450s is associated with the production of hydroxyl radicals in
vivo.
Quigley et al. (17) determined the role of hypertension, OS,
and inflammation on kidney damage in a rodent model of obesity
and diabetes. Their results suggest that obese deoxycorticos-
terone acetate-salt (DOCA-salt) hypertensive mice exhibited a
greater renal injury than lean DOCA-salt hypertensive mice in a
manner independent of blood pressure, and this renal injury was
associated with obesity-related pre-existing renal OS.
Finally, although many clinical investigations have found a
relationship between hearing loss and diabetes mellitus, the
pathophysiology of this effect remains controversial. In this
sense the outcome of the study by Aladaq et al. (18) suggest that
OS may play an important role in hearing impairment in diabetic
patients. In this process, increased protein oxidation appears to
be more important than lipid peroxidation. Nitric oxide may
have a protective effect on hearing, as may some nonenzymatic
antioxidants such as vitamin C and E.
Conclusion
A precise chromatography method was developed and vali-
dated for determining 2,3-DHBA and 2,5-DHBA. This method
provides reliable results and is an additional detection method
for determining oxidative damage in pathologies that have been
associated with OS, such as diabetes. Furthermore, with this
method it will be possible to detect at a very early stage the
degree of organic damage produced by an increase in free radi-
cals, as well as to monitor the evolution of the disease. The
method is also inexpensive, easy to run, simple, and quick with
excellent reproducibility.
On the other hand, the association of OS in vivo with salicylate
hydroxylation products in patients with diabetes mellitus is a
biochemical marker for monitoring disease progression, compli-
cations, and a response to treatment with antioxidant substances
and pharmacological management indicated.
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